Economics of Age-Regression Jan 1, 2023

◉ An Emerging Opportunity is developing to:

◉ Reduce Healthcare Cost by 80%

◉ Simply by Treating Aging as A Disease

Age-Regression interventions represent the greatest profit opportunity the biotech and pharmaceutical industry has ever seen. It also represents the greatest threat they have ever faced. That threat extends to the entire healthcare ecosystem.

Although a boon to humanity, without careful planning this advance could cause the collapse of our healthcare systems. No industry is prepared to withstand an 80% loss of their income.

Public health is defined as “The art and science of preventing disease, prolonging life and promoting health through the organized efforts and informed choices of society, organizations, public and private communities, and individuals.” With the emergence of treating aging to prevent diseases, this definition becomes prothetic.

◉ Treating Aging as the Primary Disease; Prevents and Resolves all Other Age Related Diseases

“Almost every single form of human morbidity and mortality has an age-related component to it.”

George Church

As indicated by Dr. Sinclair’s quote in the graphic above, reversing aging prevents / resolves the majority of diseases associated with aging. This includes the entire list of 92 diseases denoted in the table on the right and the primary diseases we commonly associate with aging in the graphic above right.

Research has established that aging is the major underlaying and driving factor in the development of 85% of all diseases, with the exception of communicable diseases which account for 15% and are primarily caused by viruses and bacteria. Furthermore, many bacterial infections that are prevalent in older adults should also be regarded as aging-related diseases. This highlights the importance of age-regressive regimens, which possess the ability to reverse biological aging. The benefits of these regimens include:

◉ Effective Age-Regression Represents a Radical Paradigm Shift in Public Health and Medicine.

◉ Substantially Reduce Healthcare Costs Between 50 and 90%.

◉The Economic Impact of Effectively Addressing Aging has the Potential to Dramatically Reduce the US Debt Crisis, Saving Medicare and Social Security for Future Generations.

The compression of disease into the later stages of a longer lifespan significantly lowers healthcare costs for both patients and healthcare providers, across the entire healthcare spectrum. Not only are costs reduced, but they are also spread over a longer lifespan, leading to a decreased annual economic burden on individuals and the healthcare system. The majority of disease-related costs are shifted to the final months of life. The maximum extent to which lifespan can be extended remains a very open question.

◉ Can We Really Consider Aging a Disease?

In many ways, the question has become irrelevant, because multiple research groups are already successfully treating aging, like any other disease, regardless of how the process is viewed or classified.

These groups are resetting the biological age of animals to a much younger age state in their studies, rather than simply slowing the aging process. [R1]  Dr. Harold Katcher recently completed a study in rats that has produced the longest-lived, Sprague-Dawley rat ever.  What is more notable is that rat; “Sima,” remained healthy up until the very last few days of her very long existence, dramatically demonstrating the decreased incidence of diseases and increased health-span scientist now attribute to successful age regression. 

To truly grasp the intrinsic link between aging and its substantial economic ramifications on healthcare, it is crucial to understand that age-regression is not just a viable and achievable goal, but that it has become a universally accepted reality by the scientific communities involved in aging research. This realization will seemingly spring onto the general populations, collective social consciousness in the next 24 to 36 months.  

If healthcare professionals and legislators don’t have a firm grasp of this inevitability, we could lose the only opportunity we will have to adequately plan and prepare for the dramatic and impending consequences of age-regression interventions.  How many business can you think of that would be able to withstand an 80% reduction to their income? When that business is our Healthcare infrastructure - advance preparations becomes imperative.

The fellowing sections provide an overview of the key points that will drive the discussion surrounding age-regression. A brief overview of the science underpinning these emerging age regressive therapeutics is also provided below.

 1) The Many Advantages of Treating Aging as a Disease, versus Treating Individual Diseases

◉ Can Age-Regression can actually be Accomplished?

◉ 60% of older adults have 2 or more chronic conditions

1) The Many Advantages of Treating Aging as a Disease, versus Treating Individual Diseases

◉ About 85% of older adults have at least one chronic disease.

◉ 60% of older adults have 2 or more chronic conditions

Treating Aging as the Primary Disease; Prevents and Resolves all Other Age-Related Diseases

It is now evident that an increased age, dramatically increases susceptibility to acquiring a disease of aging, and acquiring a disease of aging creates an immunological and systemic, window-of-opportunity, to acquire another disease, again accelerating the age-state of the individual.  More aging equates too more disease, more disease equals more aging. This destructive, synergistic cycle does not continue unabated. It has a finite, irresolvable and ignominious, endpoint.  Death is the ultimate negative consequence of aging.  Disease is the deleterious mechanistic agent that delivers us to that final biological end-point.  

“Human and animal longevity is directly bound to their health span. While previous studies have provided evidence supporting this connection, therapeutic implementation of this knowledge has been limited. Traditionally, diseases are researched and treated individually, which ignores the interconnectedness of age-related conditions, necessitates multiple treatments with unrelated substances, and increases the accumulative risk of toxic side effects.”

George M Church et al. 2019

2) Greater Health-Span, Compresses Diseases into a Smaller Window at the End of a Longer Life-Span

Effectively treating aging does not completely eliminate the diseases associated with aging. It does however compress them into smaller and smaller windows as the age-regressive treatments become more effective.

The disease free period of longer life is referred to as Health-Span. Detailed below.

The illustration below provide two perspectives on that age regression therapies have on disease, health and longevity. The top section identifies causes of death by age and we demonstrate the compression of those disease into small windows occurring later in life as a direct result of these interventions.

Below the cause of death illustration is a table graph clearly defining the later occurrence of all age related diseases and the improvement in health-span and lifespan that results.

From a societal perspective, the greatest benefit will come from the delay or elimination of disease, not an extension of lifespan. Luckily it’s not a case of either/or, as improvements in health-span have a direct effect on prolonging lifeslpan as all of modern medicine has demonstrated.

4) U.S. Current Annual Health Care Expenditures Account for $4,300,000,000.00, (4.3 Trillion dollars) or 18.3% of the entire US Gross Domestic Product [C2] This is projected to increase to 6.8 Trillion dollars by 2030[C3]

Projected reductions of current expenditure levels would result in saving amounting to:

◉ 50% Reduction would save approximately

$2.15 Trillion dollars a year.

◉ 90% Reduction would save approximately

$3.87 Trillion dollars a year.

Currently Americans, on average, are each spending $12,914 a year on healthcare, representing 18.3% of the nation's Gross Domestic Product each year.  4.3 Trillion dollars last year, the highest healthcare cost per capita in the world.

By 2027, US healthcare costs could be $590 billion higher than the projected $5.8 trillion expected in the estimates made pre-COVID-19 (in 2019). Heightened inflation accounts for $370 billion of this difference,1 of which 40 percent is driven by elevated clinical labor inflation rates linked to a shortage of clinical staff. Source: The gathering storm: The uncertain future of US healthcare

85% of all disease that afflict humans as they age, are non-communicable diseases.  85% thus becomes the upper range of potential reductions to the cost of healthcare by addressing aging. 

85% would produce a reduction of all US healthcare expenditures of 3.655 Trillion dollars a year.[C2]

National Health Expenditures (NHE)

• NHE grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP).

• Medicare spending grew 8.4% to $900.8 billion in 2021, or 21 percent of total NHE.

• Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17 percent of total NHE.

• Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28 percent of total NHE.

• Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10 percent of total NHE.

• Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14 percent of total NHE.

• Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020.

• Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020.

• Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020.

• The largest shares of total health spending were sponsored by the federal government (34 percent) and the households (27 percent). The private business share of health spending accounted for 17 percent of total health care spending, state and local governments accounted for 15 percent, and other private revenues accounted for 7 percent.

◉ Every Element of Healthcare will be Impacted, Including:

⫸ Individuals; ⫸ Healthcare Providers, (Physicians, Nurses, Technicians, Office Staff); ⫸  Pharmacies; ⫸ Laboratory Services; ⫸ Imaging and Radiological ; ⫸ Outpatient Services; ⫸  Nursing Homes; ⫸ Rehabilitation centers; ⫸ Hospitals; ⫸ Insurance Companies; ⫸  Biotechs / Pharmaceuticals; ⫸  Medicare / Social Security; ⫸ Federal, State and Local Governmental Healthcare Agencies.

If the US healthcare infrastructure was suddenly reduced by 85% the healthcare industry as we now know it, will cease to exists.

The economic impacts of reduced disease burden from age regression therapies are currently difficult to predict. Cost, and availability of these therapies will likely be factors limiting adoption over the next several years, until they become more available and widely accepted. The lag in cost benefits also makes economic projections challenging. Insurance cost reductions will certainly lag behind actual healthcare cost reductions. While age-related diseases account for approximately 85% of all human ailments and chronic diseases, resolution or delay of aging will not necessarily resolve all of those diseases immediately or completely.

The Pharmaceutical industry's lobbying arm is widely recognized as one of the most powerful lobbying groups in existence, with the ability to influence government policies and regulations that impact their business interests through financial contributions, media campaigns, and other advocacy efforts. Their strength and influence often leads to favorable outcomes for the industry, such as high drug prices and the protection of patent rights. However, this has also generated criticism from those who believe that the public interest is not adequately represented in decision-making processes affecting public health and access to affordable medication. The pharmaceutical industry's lobbying power may significantly delay access to age regression therapies, which pose a threat to both profits and, in some circumstances, their survival. The potential loss of between 50% and 85% of their business's income, is a formidable challenge that few businesses of any type could withstand.

Different economic models can be formulated predicated on the assumptions that these treatments will be; safe, effective and ubiquitously available at some point in the near future. The cost of age regression therapies will also have a direct impact on their adoption. It is also likely that the adoption curve will mirror that of the health insurance industry.  Younger, less affluent individuals opting to forgo the cost until they enter the demographic target of older and more affluent.  The occurrence of the first disease associated with aging will also drive a large segment of the population to enter this market. 

◉ How Do We Define; “Near Future?"

Over the last five years, it has been virtually impossible to submit an new drug application (NDA) to the FDA with an indication of "aging," because the FDA and indeed the greater scientific community did not consider aging a disease, but rather a natural biological process. Therefore, when it has became evident that some drugs held the potential to retard or regress aging, new NDAs were still required to identify a specific disease or medical condition already recognized by the FDA. Many biotechs and pharmaceutical companies have submitted NDAs for disease indications, such as sarcopenia and neurological diseases, that are indicative of disease causing molecular pathways that are, in and of themselves, an extension of a key aging pathway.

Approval of these stealth applications will unleash drugs with much broader therapeutic profiles than any drugs released before. Many of these drugs are now in phase I and II human clinical trials for disease indications that would not immediately indicate their broader therapeutic potential.   That development window puts them into a release time frame of approximately 24 to 36 months.

Multiple “early stage,” research groups, that have effectively demonstrated age regression therapeutics in animal models are actively considering alternative routes to entering the market. These companies are not flaunting the FDA’s regulations or authority, but devising strategies where they will provide marketable products without medical claims, relaying on word of mouth and the internet to educate the market.

Some effective treatments are already accessible. One such example is therapeutic plasma exchange which effective dilutes the plasma fraction resulting in a temporary improvement in biological age. The internet now provide access to many unapproved drugs and many websites and blogs describe the therapeutic results of multiple age regressive drugs.

Finally as advocated on this site, nutritional supplements are already providing a bridge to address the emerging age regressive molecular pathways. The effectiveness of this route will improve as the research continues to disclose the most effective pathways involved in age regression.

Consider a situation were scientist disclose that humans have been successfully treated for aging. As a result the diseases that afflicted them were resolved without any distress or toxicities. If you or a dear family member are at the brink of death, how strenuously would you be advocating for access to this treatment modality. I fully expect this hypothetical to become reality within the next 36 months.

The demand will be unprecedented until it is met and as described above, multiple pathway will emerge to meet this demand. Writers for lay press publication are beginning to get the message as well. The title of this recent Wired article seems to mirrors this sentiment. “A Drug to Treat Aging May Not Be a Pipe Dream.”

The fellowing factors must be considered as variables;

1) Current costs of healthcare, 2) Effectiveness of an Aging Intervention, 3) Availability of Aging Intervention, 4) Cost of Aging Intervention, 5) Risk or safety profile of Aging Intervention, 6) Impact on Diseases of Aging, and 7) Extension of Life Span.

There are many componments to US healthcare infrastructure that will be impacted by this paradigm shift in approaching the treatment of the vast majority of diseases afflicting humans.

 ◉ Age-Regression.Com tracks and documents breakthroughs in age-regression and the various treatments being developed to achieve its benefits. Learn about each treatment modality in the "Treatment Core" pages accessible from the top menu. A partial list of the leading researches involved in this endeavor are provided on the introduction page. Prediction that these treatments are still 5 to 10 years away are made on the basis and prior experience with historical clinical and regulatory research time-lines, normally encountered in drug-development.  Those drugs treated only one disease, often with quality of life diminishing side effects. Now envision a drug that will both resolve all diseases associated with aging and simultaneously reset you biological age to a much younger state with the associated energy and vitality we all associate with youth. What will the economic and political demand be for that drug. Would it exceed the demand and the speed of development we saw with COVID vaccines?  

◉ Current and working Definition of Aging

Aging is the result of epigenetic alterations, specifically methylation additions, to the DNA of cells, which progressively obstruct the accessibility of crucial genetic information. This leads to the progression of aging and the promotion of greater than 80% of all diseases. Chronokines, a subcategory of the proteome (the complete collection of proteins found in plasma), facilitate communication and regulation of the organism's systemic cell state, which includes its immune status and biological age, to all other cells through a complex feedback loop, as depicted in the illustration below.

This new definition provides two powerful points of intervention: 1) Selectively removing the accumulating aging-related epigenetic marks and/or 2) reintroducing a younger set of Chronokines to redirect the systemic cell state to a younger set-point. As the graphic below demonstrates, the two are intrinsically linked.

1) EPIGENETICS: Epigenetics refers to modifications to the genome that do not involve changes to the underlying DNA sequence, but instead alter the way the DNA is packaged and expressed. With aging, these changes can cause a decrease in the expression of genes that regulate cellular processes and contribute to the accumulation of damage and dysfunction, leading to the hallmark signs of aging. Some of the epigenetic changes that occur with aging include changes to DNA methylation patterns, changes in histone modification, and changes in non-coding RNA expression. These changes can have a direct impact on cellular processes, such as oxidative stress and inflammation, and can contribute to the development of age-related diseases. However, research has shown that some of these epigenetic changes may be reversible, suggesting that the aging process may be somewhat malleable and that certain interventions could be used to slow or even reverse aging.

2) CHRONOKINES: Chronokines are a newly discovered class of proteins that play a role in regulating aging. These proteins act as molecular clocks that control the pace of aging by regulating the rate at which cells grow and divide, and by influencing the rate at which DNA is damaged and repaired. The activity of chronokines is influenced by a number of factors, including circadian rhythms, stress, and the presence of certain chemicals in the environment.

3) RIR: Reprogrammed Induced Age-Regression (RIR) is a process that drives an individual's cell state backwards towards pluripotency. Using transcriptional factors to achieve nuclear reprogramming can drive cells to pluripotency, reverting both the age and identity of any cell to that of an embryonic stem cell (ESC). While the expression of pluripotency factors can convert somatic differentiated cells into pluripotent stem cells, partial reprogramming can reverse epigenetic markers of aging in cells, improve the capacity of aged mice to repair tissue injuries, and extend longevity in progeroid mice. As a systemic treatment in humans, the goal is incremental and partial reprogramming, not pluripotency. Multiple strategies have been developed by research groups to determine the optimal formulation of factors, doses, timing, and treatment intervals to produce the most effective age-regression therapeutic regimen. Dr. David Sinclair has implemented the first primate study incorporating the cyclic expression of Yamanaka transcriptional factors to achieve systemic age-regression.

◉ The Connection between Aging and Disease

In 2018, Stefano Salvioli et al, published “The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates.” The fellowing paragraph provides an accurate overview of the relationship between age and age-related diseases.

The question of whether old age is a disease has been debated since ancient times. In the 19th century, with the birth of modern medicine, aging and diseases were considered separate phenomena. This review challenges that view and argues that aging and age-related diseases should be considered as part of a continuum, as they share the same basic molecular and cellular mechanisms. These mechanisms include adaptation to stress, loss of proteostasis, stem cell exhaustion, metabolism derangement, macromolecular damage, epigenetic modifications, and inflammation. The difference between aging and diseases lies in the rate and intensity of cellular and molecular processes and specific organ/system predisposition. All major age-related diseases have a long incubation period where the signs of diseases are largely unobservable. This is due to the high operational redundancy of biological systems and the progressive capacity of cells and systems to adapt. [A14 GPT-S]

———————————————————————————

———————————————————————————

◉ This report serves as a wake-up call to every stakeholders in healthcare, including legislators, economists, journalists, providers and developers. It highlights the imminent and transformative changes that will result from the successful regression of aging. To dispel any doubts among those unfamiliar with this research, the report provides a clear and concise overview of the relevant studies and emerging evidence. Given the potential economic impact, preparation is imperative and failure to acknowledge the inevitability of this healthcare revolution will hinder our ability to prepare for its wide-ranging effects on the healthcare system, the wellbeing of every individual and our economies.

 4) The Economic Impact of Effectively Addressing Aging has the Potential of Dramatically Reducing the US Debt Crisis.

Effectively treating aging does not completely eliminates the diseases associated with aging, it does however compress them into a smaller and smaller window as the age-regressive treatments become more effective. The disease free period of longer life is referred to as Health-Span. Shown in the graphic below in the Today, Tomorrow and Future time lines, below the Causes of death illustration. This dramatically reduces the total cost of all healthcare for both recipients and providers, across the entire spectrum of the healthcare ecosystem. Not only are healthcare cost dramatically reduced, but these reduced cost are now distributed across a much longer period of time, a dramatically longer Life-Span and thus the annual economic burden on the individual and the healthcare system is greatly diminished with the majority of cost associated with the burden of disease moved to the final months of life.

5) Current Annual Health Care Expenditures Account for $4,300,000,000.00, (4.3 Trillion dollars) or 18.3% of the entire US Gross Domestic Product [C2]

The economics of any significant reduction in disease burden from age regression therapies are impossible to accurately model at this point in time. Although diseases of aging represent 85% of all human afflictions, resolution or delay of aging will not resolve all of those diseases immediately or completely. The attack rate of the implementation of these aging interventions will take several years with adoption, cost and availability being limiting factors. Lags in recouping these cost benefits will also complicate economic projections. Reducions in insurance cost will certentailly lag behind the actual healthcare cost reductions. One unknown question in accessing this ground breaking advancement in healthcare is; how much will the pharmaceutical industries lobbying arm be able to delay the access to these disease ameliorating therapies. Remember that this is the most powerful lobbying group in existence and any reduction in disease is a direct and proportional reduction to the income of the pharmaceutical industries bottom line. Age regression therapies will be viewed as not just as a threat to their bottom line, but as a threat to their existence.

Different economic models can be formulated predicated first on the assumption that these treatments are both safe and effective. on these limiting factors: 1) Current costs of healthcare, 2) Effectiveness of an Aging Intervention, 3) Availability of Aging Intervention, 4) Cost of Aging Intervention, 5) Risk or safety profile of Aging Intervention and 6) Impact on Diseases of Aging.

———————————————————————————

From our own personal experiences and observations, we all know that young individuals are unlikely to get the diseases shown in the graphic below and the older you become, the more likely it becomes that you will.

Thus, It becomes axiomatic that successfully treating and regressing aging would be a dramatic disease preventive intervention, improving quality of, and extending the length of life for everyone on this planet.

Currently Americans, on average, are each spending $12,914 a year on healthcare, representing 18.3% of the nation's Gross Domestic Product each year.  4.3 Trillion dollars last year, the highest healthcare cost per capita in the world. [C2]

85% of all disease that afflict humans as they age, are non-communicable diseases.  Thats the approximate percentage that healthcare cost would be reduced from successfully treating the underlying causes of aging. Thats a cost saving of 3.655 Trillion dollars a year.

Diseases of aging will still occur, but at a much delayed rate and moved to the very end of an individuals extended lifespan.

This report is intended for legislators, economists and healthcare providers, as an alert to the impending tsunamic changes in healthcare created by successfully regressing age. A brief overview of the relevant research is presented for the individuals who are still skeptical that safe and effective treatments to regress aging will become available within a relatively short period of time. If you don’t believe, you can’t prepare. This revolution in healthcare will have profound economic consequences on each and every component of the healthcare ecosystem including:

Individuals; ⫸ Healthcare Providers, (Physicians, Nurses, Technicians, Office Staff); ⫸  Pharmacies; ⫸ Laboratory Services; ⫸ Imaging and Radiological ; ⫸ Outpatient Services; ⫸  Nursing Homes; ⫸ Rehabilitation centers; ⫸ Hospitals; ⫸ Insurance Companies; ⫸  Biotechs / Pharmaceuticals; ⫸  Medicare / Social Security; ⫸ Federal, State and Local Governmental Healthcare Funding Agencies.

If, as a legislator, you are unaware of these dramatic advances or skeptical about the validity of these claims, the introduction page of this website provides an overview of the current state of the research. The majority of the pages on this site are detailed reviews of different research groups approachs to inducing age-regression in any mammal or organism including humans. Resistance to these age-regressive advances by the pharmaceutical industry and their lobbying groups are inevitable.

Health care expenditures are currentely projected to increase every year at a 2.71% rate.

Aging has been reversed in multiple animal models utilizing multiple modalities. One group has accomplished this historical feat using only two, orally administered agents, a small molecule and an already approved drug. The Sinclair group from Harvard medicine has recently started a primate study in preparation for human studies. Advancements in age regression research are detailed on multiple pages of this site. All of us have an intuitive sense of the direct connection between disease and age. Young individuals for the most part do not get sick and as we age you do. What was unknown before is the direct melocule connection between aging and disease. The focus of this page however is on the sunomie reduction in healthcare cost, that regressing age will produce. 85% of all diseases inflecting mankind are referred to as diseases of aging. As a group on the economics of every component of healthcare. by reducing disease burden in adults by 85% will have

This research has been advancing at an unparalleled pace. Scientiest currently estimate that an age regressing modality will become available to individuals in 7 to 10 years, but importantly the race is on. As the mechanistic processes emerges to accomplish that goal, the desire to become the first research group/biotech/pharmaceutical to produce a practical solution to reverse or rejuvenate aging becomes both financially and professionally compelling. The will to survive will drive many individuals to access the same emerging technologies much sooner that that timeline. In all probability effective age-regressive strategies will become generally known and available within the next 24 months.

It is important to note that although multiple scientific groups know how to regress the age of an organism by multiple methods and modalities, the same scientist don’t fully understand the underlaying science that is causing this age reversal. If that sounds unlikely, keep in mind that mankind has been using willow bark as a pain killer for 3500 years. The drug was synthesized in 1899 by Bayer and marketed as Aspirin. The analgesic and antinflamatory effects of aspirin remained unknown until 1971. The entire pharmacological profile of aspirin is still being illicuidated.

Age regression interventions that prevent disease in addition to increasing life-span will produce cost reductions to individuals, insurance companies, HMO’s, governmental programs like medicare and social security. I am not ignoring the inescapable fact that individuals will still get sick and die, but that process will be truncated into a much shorter timeline at the very end of a much longer and healthier life.   When the biological age of all of us is dialed back to a younger state, diseases other than communicable will be be all but eliminated. This last statement is predicated on recent, emerging research accomplished with Yamanaka factors induced by small molecules.  These treatments will soon become available without commercial or regulatory restraint. I am aware that sounds very naive and only time will tell, but this webpage provides additional insights into this statement. 

Because a younger biological age state blocks the emergence of diseases of aging, research on that large body of diseases will no longer be prioritized for funding. See: is aging a disease here? 

Projected NHE, 2019-2028:

• National health spending is projected to grow at an average annual rate of 5.4 percent for 2019-28 and to reach

  • $6.2 trillion by 2028. 

• Because national health expenditures are projected to grow 1.1 percentage points faster than gross domestic product per year on average over 2019–28, the health share of the economy is projected to rise from 17.7 percent in 2018 to

  • 19.7 percent in 2028. 

• Price growth for medical goods and services (as measured by the personal health care deflator) is projected to accelerate, averaging 2.4 percent per year for 2019–28, partly reflecting faster expected growth in health sector wages. 

• Among major payers, Medicare is expected to experience the fastest spending growth (7.6 percent per year over 2019-28), largely as a result of having the highest projected enrollment growth.

• The insured share of the population is expected to fall from 90.6 percent in 2018 to 89.4 percent by 2028.

• Current expenditures are 4.3 Trillion In National Health Spending

COST OF HEALTHCARE BY DISEASE, AGE AND COUNTRY

The 2016 “Cause of Deaths,” graphic on the right, provides a graphic of all diseases including diseases associated with aging; Neoplasms/Cancer, Cardiovascular Diseases, Respiatory Diseases, Liver Disease, Digestive Diseases, Diabetes, Neurological Disease and Musculskelitol Disease. All of the diseases that are intrinsically linked with aging are all colored in varrarying shades of blue. Visualizing this graph without the blue colored diseases clearly demonstrats the dramatic impact that resolving and delaying those causes of death would have on humanity and the cost associated with healthcare. [A15]

The (Today, section of the chart above) illustrates your risk of dying from a specific disease at a given age.  The corresponding timeline graph at the bottom provides the duration of health-span versus the beginning of the progression of disease, and ultimately death. 

In the near future (Tomorrow, section of the chart above) we will be able to shift this burden of disease into a much smaller period of time and move it later in what will likely be a longer and much healthier lifespan.  The (Future) holds the promise of living a long, healthy and productive life with the burden of disease compressed into the very last years or even months of life. [7] Source: How you will die

◉ Profound advantages (detailed below) will Inure to the political party that is associated with facilitating advancing Age-Regression.